Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 62.8%

Neg 0% Neu 62.8% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.